Popular:
Pharming Group N.V. (PHAR)
Intrinsic Value
DCF Not Suitable for PHAR
Revenue ($362M) below $1B threshold — insufficient business scale for DCF.
Alternative Approach:
Use EV/Sales vs. industry peers for growth-stage companies.
Pharming Group N.V. (PHAR) Intrinsic Value
DCF-based fair value calculation with Bear, Base, and Bull scenarios
Frequently Asked Questions
Is PHAR stock undervalued or overvalued?
Insufficient data to compute DCF valuation for PHAR. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
What is PHAR's intrinsic value?
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
How is PHAR's fair value calculated?
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For PHAR, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.